167 related articles for article (PubMed ID: 19232697)
1. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy for prostate cancer.
Jakobovits A
Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
[TBL] [Abstract][Full Text] [Related]
3. Use of monoclonal antibodies in the treatment of ovarian cancer.
Mabuchi S; Morishige K; Kimura T
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):3-8. PubMed ID: 19770762
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ovarian cancer by monoclonal antibodies.
Mabuchi S; Kimura T
Discov Med; 2010 Mar; 9(46):197-203. PubMed ID: 20350485
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract][Full Text] [Related]
6. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
7. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for colorectal cancer.
Hwang J; Marshall JL
Curr Opin Investig Drugs; 2006 Dec; 7(12):1062-6. PubMed ID: 17209523
[TBL] [Abstract][Full Text] [Related]
9. Overview of monoclonal antibodies in cancer therapy: present and promise.
Stern M; Herrmann R
Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905
[TBL] [Abstract][Full Text] [Related]
10. Targeting signaling pathways in ovarian cancer.
Reibenwein J; Krainer M
Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
[TBL] [Abstract][Full Text] [Related]
11. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
12. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
13. Vaccines and monoclonal antibodies.
Michaeli D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S82-6. PubMed ID: 16399439
[TBL] [Abstract][Full Text] [Related]
14. Consolidation therapy in ovarian cancer: where do we stand?
Dearnley DD; McMeekin DS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
16. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
Dinh P; Harnett P; Piccart-Gebhart MJ; Awada A
Crit Rev Oncol Hematol; 2008 Aug; 67(2):103-12. PubMed ID: 18342536
[TBL] [Abstract][Full Text] [Related]
17. Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.
Berardi R; Verdecchia L; Paolo MD; Giampieri R; Scartozzi M; Pierantoni C; Bianconi M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2009 Mar; 69(3):223-36. PubMed ID: 18722785
[TBL] [Abstract][Full Text] [Related]
18. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
19. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith RF; Buchsbaum DJ; Alvarez RD; LoBuglio AF
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5643s-5645s. PubMed ID: 17875801
[TBL] [Abstract][Full Text] [Related]
20. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
